Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

 8 of 9 participants (89%) treated in the 240mg and 360mg single dose cohorts achieved a complete response

8 of 11 participants (73%) enrolled in the 180mg Q8W open label extension study achieved a complete response at 12 weeks

Read more at globenewswire.com